

Stockholm, 31 May 2012

## Sobi appoints Birgitte Volck as Chief Medical Officer

Birgitte Volck has been appointed Senior Vice President, Chief Medical Officer at Sobi with responsibility for Clinical Development, Regulatory Affairs, Drug Safety and Medical Affairs.

Birgitte Volck is currently Executive Development Director, Bone, Neuroscience & Inflammation at Amgen Limited in Uxbridge, UK. She has held several senior positions within Amgen since 2007, including Executive Medical Director, Nordic & Baltic Region. Prior to Amgen she was Nordic Medical Director & Project Director at Genzyme A/S in Denmark 2004-2007, and Vice President, Clinical Development & Medical Affairs at Pharmexa A/S in Denmark 2001-2004.

During 1991-2000 she had various clinical and scientific assignments, mainly within rheumatology, at the Copenhagen University Hospitals. She holds a PhD and has published a number of scientific papers related to inflammation, connective tissue metabolism, biomarkers and arthritis.

Birgitte Volck, 49 years, is MD and PhD from the University of Copenhagen. She will report to CEO Geoffrey McDonough and will be a member of the Executive Leadership Team. She will assume her position on August 1, 2012.

“We are delighted to welcome Birgitte to Sobi. With her extensive experience in drug development and integrated and patient focused Medical Affairs, Birgitte will bring a perspective and drive to our medical organization as we advance our life cycle management and late stage pipeline projects,” says Geoffrey McDonough, CEO of Sobi.

### **For further information, please contact:**

Åsa Stenqvist, Head of Communications and Investor Relations  
Tel.: +46 8 697 21 88

### **Swedish Orphan Biovitrum (Sobi)**

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at [www.sobi.com](http://www.sobi.com).

*The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 31 May 2012 at 08.30 CET.*